Literature DB >> 1415152

Interpretation and estimation of vaccine efficacy under heterogeneity.

M E Halloran1, M Haber, I M Longini.   

Abstract

Interpretation and estimation of vaccine efficacy is complicated when the vaccine effect is heterogeneous across vaccinated strata. If a person has a certain susceptibility, or probability of becoming infected conditional on a specified exposure to infection, then one effect of a vaccine would be to reduce that susceptibility, possibly to zero. Vaccine efficacy is a function of the relative susceptibilities in the vaccinated and unvaccinated persons. Under heterogeneity of vaccine effect, a general expression for a summary vaccine efficacy parameter is a function of the vaccine efficacy in the different vaccinated strata weighted by the fraction of the vaccinated subpopulations in each stratum. Interpretation and estimability of the summary vaccine efficacy parameter depends on whether the strata are identifiable, and whether the heterogeneity is host- or vaccine-related. Bounds are derived for the summary vaccine efficacy when the strata are not identifiable for the case of an outbreak of an acute infectious disease. The upper bound assumes that everyone is equally affected by the vaccine, and the lower bound assumes that some are completely protected while others have no protection. The biologic interpretation of the two bounds is different.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1415152     DOI: 10.1093/oxfordjournals.aje.a116498

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  48 in total

1.  A method for estimating time dependent intervention benefits under arbitrarily varying age and exogenous components of hazard.

Authors:  R C Brunet; C J Struchiner; A Loinaz
Journal:  Lifetime Data Anal       Date:  2001-12       Impact factor: 1.588

2.  Mathematical models for HIV transmission dynamics: tools for social and behavioral science research.

Authors:  Susan Cassels; Samuel J Clark; Martina Morris
Journal:  J Acquir Immune Defic Syndr       Date:  2008-03-01       Impact factor: 3.731

3.  EPIDEMIOLOGICAL CONSEQUENCES OF IMPERFECT VACCINES FOR IMMUNIZING INFECTIONS.

Authors:  F M G Magpantay; M A Riolo; M Domenech DE Cellès; A A King; P Rohani
Journal:  SIAM J Appl Math       Date:  2014       Impact factor: 2.080

4.  Combating pertussis resurgence: One booster vaccination schedule does not fit all.

Authors:  Maria A Riolo; Pejman Rohani
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-20       Impact factor: 11.205

5.  Vaccine impact in homogeneous and age-structured models.

Authors:  F M G Magpantay
Journal:  J Math Biol       Date:  2017-04-17       Impact factor: 2.259

6.  Estimating Direct and Indirect Protective Effect of Influenza Vaccination in the United States.

Authors:  Nimalan Arinaminpathy; Inkyu Kevin Kim; Paul Gargiullo; Michael Haber; Ivo M Foppa; Manoj Gambhir; Joseph Bresee
Journal:  Am J Epidemiol       Date:  2017-07-01       Impact factor: 4.897

7.  A Novel Representation of Vaccine Efficacy Trial Datasets for Use in Computer Simulation of Vaccination Policy.

Authors:  Mohammadamin Tajgardoon; Michael M Wagner; Shyam Visweswara; Richard K Zimmerman
Journal:  AMIA Jt Summits Transl Sci Proc       Date:  2018-05-18

8.  Measurement of Vaccine Direct Effects Under the Test-Negative Design.

Authors:  Joseph A Lewnard; Christine Tedijanto; Benjamin J Cowling; Marc Lipsitch
Journal:  Am J Epidemiol       Date:  2018-12-01       Impact factor: 4.897

9.  Heterogeneity in malaria exposure and vaccine response: implications for the interpretation of vaccine efficacy trials.

Authors:  Michael T White; Jamie T Griffin; Chris J Drakeley; Azra C Ghani
Journal:  Malar J       Date:  2010-03-23       Impact factor: 2.979

10.  Impact of stochastically generated heterogeneity in hazard rates on individually randomized vaccine efficacy trials.

Authors:  Rebecca Kahn; Matt Hitchings; Steven Bellan; Marc Lipsitch
Journal:  Clin Trials       Date:  2018-01-27       Impact factor: 2.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.